Current Report Filing (8-k)
March 02 2023 - 7:56AM
Edgar (US Regulatory)
false0001133416The Nasdaq Stock Market00011334162023-03-022023-03-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 2, 2023
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
001-31791
|
04-3562325
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock $0.001par value per share
|
GALT
|
The Nasdaq Stock Market
|
SECTION 8 – OTHER ITEMS
On March 2, 2023, Galectin Therapeutics Inc. (the “Company) issued the press
release attached hereto as Exhibit 99.1.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 |
Financial Statements and Exhibits.
|
|
(d) |
Exhibits. The following exhibit is filed with this Report:
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Galectin Therapeutics Inc.
|
|
|
|
Date: March 2, 2023
|
By:
|
/s/ Jack W. Callicutt
|
|
|
|
Jack W. Callicutt
|
|
|
Chief Financial Officer
|
- 3 -
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2023 to Aug 2024